Baraclude continues to thrive in the face of limited competition

The domestic hepatitis B market is still dominated by Baraclude (entecavir) with better efficacy and safety profiles and this trend likely to continue.

Developed by the US based Bristol-Myers Squibb, Baraclude does not offer a paradigm change compared to Zeffix or Hepsera, the current antiviral standards of care, but does have superior potency and an improved resistance profile.

The sales...